• 
  Marie Paule Sablin, Pierre Gestraud, Sarah Flora Jonas, Constance Lamy, Magali Lacroix-Triki, et al.. Copy number alterations in metastatic and early breast tumours: prognostic and acquired biomarkers of resistance to CDK4/6 inhibitors. British Journal of Cancer, In press, ⟨10.1038/s41416-024-02804-6⟩. ⟨hal-04683939⟩
• 
  Mohamed Bouchahda, Valérie Boige, Denis Smith, Abdoulaye Karaboué, Michel Ducreux, et al.. Early tumour response as a survival predictor in previously- treated patients receiving triplet hepatic artery infusion and intravenous cetuximab for unresectable liver metastases from wild-type KRAS colorectal cancer. European Journal of Cancer, 2016, 68, pp.163-172. ⟨10.1016/J.EJCA.2016.09.011⟩. ⟨hal-04545408⟩
• 
  Patricia Pautier, Antoine Italiano, Sophie Piperno-Neumann, Christine Chevreau, Nicolas Penel, et al.. Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial.. Lancet Oncology, 2022, Lancet Oncology, 23 (8), pp.1044-1054. ⟨10.1016/S1470-2045(22)00380-1⟩. ⟨hal-04387055⟩
• 
  J.Y. Blay, N. Penel, T. Valentin, P. Anract, F. Duffaud, et al.. Improved nationwide survival of sarcoma patients with a network of reference centers. Annals of Oncology, 2024, 35 (4), pp.351-363. ⟨10.1016/j.annonc.2024.01.001⟩. ⟨inserm-04658953⟩
• 
  Coline Montégut, Jean-Sébastien Guillamo, François Ducray, Caroline Dehais, Cohen-Jonathan Moyal Elisabeth, et al.. Predictive geriatric factors in elderly patients treated for idh-mutant high-grade gliomas: a French Pola network study. Neuro-Oncology, 2021, 23 (6), pp.153. ⟨10.1093/neuonc/noab196.600⟩. ⟨hal-03600574⟩
• 
  Emeline Tabouret, François Bertucci, Jean-Yves Pierga, Thierry Petit, Christelle Levy, et al.. MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study. Oncotarget, 2016, 7 (14), pp.18531-18540. ⟨10.18632/oncotarget.7612⟩. ⟨hal-03623733⟩
• 
  Anne Patsouris, Kadija Diop, Olivier Tredan, Daniel Nenciu, Anthony Gonçalves, et al.. Rucaparib in patients presenting a metastatic breast cancer with homologous recombination deficiency, without germline BRCA1/2 mutation. European Journal of Cancer, 2021, 159, pp.283-295. ⟨10.1016/j.ejca.2021.09.028⟩. ⟨hal-04522229⟩
• 
  Quentin Dominique Thomas, Amal Boussere, Jean-Marc Classe, Christophe Pomel, Hélène Costaz, et al.. Optimal timing of interval debulking surgery for advanced epithelial ovarian cancer: A retrospective study from the ESME national cohort. Gynecologic Oncology, 2022, 167 (1), pp.11-21. ⟨10.1016/j.ygyno.2022.08.005⟩. ⟨hal-03868125⟩
• 
  P. Kubicek, A. L. Cesne, C. Lervat, M. Toulmonde, C. Chevreau, et al.. Management and outcomes of adolescent and young adult sarcoma patients: results from the French nationwide database NETSARC.. BMC Cancer, 2023, BMC Cancer, 23 (1), pp.69. ⟨10.1186/s12885-023-10556-4⟩. ⟨hal-04315885⟩
• 
  Gilles Freyer, Anne Floquet, Olivier Tredan, Aurore Carrot, Carole Langlois-Jacques, et al.. Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group. Nature Communications, 2024, 15 (1), pp.1985. ⟨10.1038/s41467-024-45974-w⟩. ⟨hal-04549309⟩
• 
  Capucine Baldini, E. Charton, E. Schultz, L. Auroy, A. Italiano, et al.. Access to early-phase clinical trials in older patients with cancer in France: the EGALICAN-2 study. ESMO Open, 2022, European Society for Medical Oncology, 7, pp.100468. ⟨10.1016/j.esmoop.2022.100468⟩. ⟨hal-04567217⟩
• 
  M. Brahmi, T. Lesluyes, A. Dufresne, M. Toulmonde, A. Italiano, et al.. Expression and prognostic significance of PDGF ligands and receptors across soft tissue sarcomas.. ESMO Open, 2021, ESMO Open, 6 (1), pp.100037. ⟨10.1016/j.esmoop.2020.100037⟩. ⟨hal-04552489⟩
• 
  Sophie Leboulleux, Christine Do Cao, Slimane Zerdoud, Marie Attard, Claire Bournaud, et al.. MERAIODE: A Phase II Redifferentiation Trial with Trametinib and 131 I in Metastatic Radioactive Iodine Refractory RAS Mutated Differentiated thyroid Cancer. Clinical Cancer Research, 2023, 29 (13), pp.2401-2409. ⟨10.1158/1078-0432.CCR-23-0046⟩. ⟨inserm-04552345⟩
• 
  Grégoire Marret, Stéphane Temam, Maud Kamal, Caroline Even, Jean-Pierre Delord, et al.. Randomized phase II study of preoperative afatinib in untreated head and neck cancers: predictive and pharmacodynamic biomarkers of activity. Scientific Reports, 2023, 13, pp.22524. ⟨10.1038/s41598-023-49887-4⟩. ⟨hal-04543900⟩
• 
  P. Sargos, J. Le Guevelou, J. Khalifa, L. Albiges, D. Azria, et al.. The role of radiation therapy for de novo metastatic bladder and renal cancers. Cancer/Radiothérapie, 2024, 28 (1), pp.56 - 65. ⟨10.1016/j.canrad.2023.02.004⟩. ⟨inserm-04517309⟩
• 
  Charlotte Demoor-Goldschmidt, Stéphane Supiot, Marc-André Mahé, Odile Oberlin, Rodrigue Allodji, et al.. Clinical and histological features of second breast cancers following radiotherapy for childhood and young adult malignancy. British Journal of Radiology, 2018, 91 (1086), pp.20170824. ⟨10.1259/bjr.20170824⟩. ⟨inserm-04439735⟩
• 
  Imène Mansouri, Rodrigue S Allodji, Catherine Hill, Chiraz El‐fayech, François Pein, et al.. The role of irradiated heart and left ventricular volumes in heart failure occurrence after childhood cancer. European Journal of Heart Failure, 2018, 21 (4), pp.509 - 518. ⟨10.1002/ejhf.1376⟩. ⟨inserm-04439245⟩
• 
  Maria John, Roberto Salgado, Thomas Gevaert, Prudence A Russell, Tom John, et al.. Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors. Advances in Anatomic Pathology, 2017, 24 (6), pp.311 - 335. ⟨10.1097/PAP.0000000000000161⟩. ⟨hal-01675236⟩
• 
  Maria John, Roberto Salgado, Thomas Gevaert, Prudence A Russell, Tom John, et al.. Assessing Tumor-infiltrating Lymphocytes in Solid Tumors. Advances in Anatomic Pathology, 2017, 24 (5), pp.235 - 251. ⟨10.1097/PAP.0000000000000162⟩. ⟨hal-01675241⟩
• 
  Manon de Vries-Brilland, Nathalie Rioux-Leclercq, Maxime Meylan, Jonathan Dauvé, Christophe Passot, et al.. Comprehensive analyses of immune tumor microenvironment in papillary renal cell carcinoma. Journal for Immunotherapy of Cancer, 2023, Journal for ImmunoTherapy of Cancer, 11 (11), pp.e006885. ⟨10.1136/jitc-2023-006885⟩. ⟨hal-04341909⟩

136

175